Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin

Ep. 72 - Outlook for Biotech M&A and Financing: Sidley's Robert Darwin

Ep. 71 - Pazdur Unplugged: FDA Director Richard Pazdur on the Past, Future of Cancer Treatments

Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

Think Fast, Talk Smart: Communication Techniques

Proposed Payment 2026, MCO Final Rule, MHPAEA Final Rule, and CMS Provider Directory Pilot

Debt Capital Markets (DCM) Explained

Ep. 70 - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine

China Summit: Reinventing Your China Strategy

What is Growth Equity? (Interview with Investor at ICONIQ Capital)

Ep. 69 - Lee Fleisher: An Insider’s Account of CMS’s Alzheimer’s Coverage Decisions

Investment banking vs private equity

Ep. 261 - China Summit: Reinventing Your China Strategy

Ep. 264 - Prepping for Trump & Alzheimer's Ethics

The MOST UNDERRATED Buy-Side Industry - Growth Equity! (TPG's $4BN Fund)

Fuerte Metals shifts focus to High-Grade Gold

Private Equity: Industry Review - Ed Mathias, The Carlyle Group

How To Speak Fluently In English About Almost Anything

Empowering Newcomers to the World of Treasury with Thomas Balish

Ep. 260 - VC Funds, New Chapter for MS, Wave's Data

Ep. 258 - Breaking the Bear: 4Q Public Markets Preview